Literature DB >> 6146337

Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.

D Gangji, M Juvent, G Niset, M Wathieu, M Degreve, R Bellens, J Poortmans, S Degre, T J Fitzsimons, A Herchuelz.   

Abstract

The influence of chronic therapy with nifedipine on the pharmacokinetics of propranolol 80 mg twice daily, metoprolol 100 mg twice daily and atenolol 100 mg once daily was investigated in eight healthy volunteers. Nifedipine 10 mg three times daily did not affect the pharmacokinetics of metoprolol and atenolol whereas nifedipine shortened the time to peak plasma concentration for propranolol by about 1 h. Propranolol, metoprolol and atenolol provoked comparable decreases in heart rate measured at rest and during exercise. The beta-adrenoceptor blocking properties of propranolol, metoprolol and atenolol were not affected by concomitant therapy with nifedipine. The present study did not show significant pharmacokinetic and pharmacodynamic interactions between nifedipine and lipophilic beta-adrenoceptor blockers.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6146337      PMCID： PMC1463260          DOI： 10.1111/j.1365-2125.1984.tb02425.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  22 in total

1.  Metabolism of metoprolol-(3-h) in man, the dog and the rat.

Authors:  K O Borg; E Carlsson; K J Hoffmann; T E Jönsson; H Thorin; B Wallin
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Inhibition of propranolol metabolism by chlorpromazine.

Authors:  R E Vestal; D M Kornhauser; J W Hollifield; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

Review 3.  Bioavailability of drugs (first of two parts).

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1974-08-01       Impact factor: 91.245

4.  Cimetidine and bioavailability of propranolol.

Authors:  M A Donovan; A M Heagerty; L Patel; M Castleden; J E Pohl
Journal:  Lancet       Date:  1981-01-17       Impact factor: 79.321

Review 5.  The clinical importance of cardioselectivity and lipophilicity in beta blockers.

Authors:  J M Cruickshank
Journal:  Am Heart J       Date:  1980-08       Impact factor: 4.749

Review 6.  Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.

Authors:  P H Stone; E M Antman; J E Muller; E Braunwald
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

7.  Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol.

Authors:  H R Ochs; G Carstens; D J Greenblatt
Journal:  N Engl J Med       Date:  1980-08-14       Impact factor: 91.245

8.  The effect of beta-adrenoceptor blockade on factors affecting exercise tolerance in normal man.

Authors:  S B Pearson; D C Banks; J M Patrick
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

9.  Interaction between oral propranolol and hydralazine.

Authors:  A J McLean; H Skews; A Bobik; F J Dudley
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

10.  Impairment of antipyrine clearance in humans by propranolol.

Authors:  D J Greenblatt; K Franke; D H Huffman
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690
View more
  14 in total

1.  Nicardipine does not influence the pharmacokinetics and pharmacodynamics of atenolol.

Authors:  I Vercruysse; D F Schoors; G Musch; D L Massart; A G Dupont
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 2.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 3.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 4.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

5.  The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol.

Authors:  H L Elliott; P A Meredith; C McNally; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 6.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

7.  Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.

Authors:  D F Schoors; I Vercruysse; G Musch; D L Massart; A G Dupont
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

8.  Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.

Authors:  T Tateishi; H Nakashima; T Shitou; Y Kumagai; K Ohashi; S Hosoda; A Ebihara
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

10.  Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats.

Authors:  I Vercruysse; D F Schoors; D L Massart; A G Dupont
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.